Skip to main content
    P

    Pfizer Inc (PFE)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $28.88
    -0.01 (-0.03%)

    Market Cap: $164.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pfizer Inc (PFE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Pfizer reported revenue of $62.58B for the fiscal year ended Dec 31, 2025, down 1.6% from the year before. That year, net income was $7.81B with a net margin of 12.5%, operating cash flow was $11.70B and free cash flow was $9.07B. The quarter ended Sep 30, 2026 had revenue of $16.58B and net income of $3.25B.

    Revenue and Margins

    The operating margin was 22.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $52.82B, a compound annual rate of 1.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$62.58B-1.6%74.3%22.8%12.5%
    Dec 2024$63.63B+6.8%71.9%19.5%12.7%
    Dec 2023$59.55B-41.1%58.1%2.1%3.6%
    Dec 2022$101.17B+24.5%66.1%35.4%31.0%
    Dec 2021$81.29B+95.2%62.1%23.9%27.1%
    Dec 2020$41.65B+1.8%79.6%19.8%22.1%
    Dec 2019$40.91B+0.2%80.3%16.4%39.3%
    Dec 2018$40.83B-22.3%78.0%13.9%27.4%
    Dec 2017$52.55B-0.5%78.6%26.1%40.6%
    Dec 2016$52.82BN/A76.7%23.0%13.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 3.1% from the year before. In the quarter ended Sep 2026, net income fell 8.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$62.58B$63.63B$59.55B$101.17B$81.29B$41.65B$40.91B$40.83B$52.55B$52.82B
    Cost of revenue$16.07B$17.85B$24.95B$34.34B$30.82B$8.48B$8.05B$8.99B$11.23B$12.32B
    Gross profit$46.51B$45.78B$34.60B$66.83B$50.47B$33.17B$32.85B$31.84B$41.32B$40.50B
    Research and development$12.05B$10.93B$10.87B$12.38B$13.83B$9.39B$8.38B$7.76B$7.68B$7.89B
    Operating income$14.24B$12.41B$1.28B$35.79B$19.43B$8.25B$6.71B$5.67B$13.72B$12.14B
    Net income$7.81B$8.06B$2.16B$31.41B$22.02B$9.20B$16.06B$11.19B$21.36B$7.25B
    EBITDAN/A$15.04B$7.35B$39.79B$29.50B$11.72B$8.97B$9.74B$18.57B$14.11B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$16.58B$15.03B$14.45B$17.56B$16.65B$14.65B$13.71B$17.76B$17.70B$13.28B$14.88B$14.57B
    Gross profit$12.55B$10.94B$10.90B$12.29B$12.48B$10.88B$10.87B$11.85B$12.44B$9.98B$11.50B$7.01B
    Operating income$3.67B$3.06B$4.03B$2.87B$3.85B$3.78B$3.74B$2.35B$4.96B$1.00B$4.10B-$4.29B
    Net income$3.25B-$237.00M$2.70B-$1.64B$3.55B$2.93B$2.97B$418.00M$4.47B$48.00M$3.12B-$3.36B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $64.80B exceeded cash and equivalents by $63.65B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$208.16B$213.40B$226.50B$197.21B$181.47B$154.23B$167.59B$159.42B$171.80B$171.62B
    Current assets$42.90B$50.36B$43.33B$51.26B$59.69B$35.07B$32.80B$49.93B$41.14B$38.95B
    Cash and equivalents$1.14B$1.04B$2.85B$416.00M$1.94B$1.79B$1.12B$1.14B$1.34B$2.60B
    Total liabilities$121.39B$124.90B$137.21B$101.29B$104.01B$90.76B$104.15B$95.66B$100.14B$111.78B
    Short-term debt$3.15B$6.95B$10.35B$2.94B$2.24B$2.70B$16.20B$8.83B$9.95B$10.69B
    Long-term debt$61.64B$57.41B$61.54B$32.88B$36.20B$37.13B$35.95B$32.91B$33.54B$31.40B
    Shareholder equity$86.48B$88.20B$89.01B$95.66B$77.20B$63.24B$63.14B$63.41B$71.31B$59.54B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$204.54B$201.13B$207.62B$208.16B$208.73B$206.09B$208.03B$213.40B$219.48B$216.19B$221.09B$226.50B
    Total liabilities$115.24B$115.64B$117.21B$121.39B$115.64B$117.08B$117.39B$124.90B$126.92B$128.22B$128.54B$137.21B
    Cash and equivalents$1.82B$976.00M$1.70B$1.14B$1.34B$1.64B$1.43B$1.04B$1.09B$1.05B$719.00M$2.85B
    Shareholder equity$89.00B$85.19B$90.10B$86.48B$92.80B$88.69B$90.34B$88.20B$92.29B$87.70B$92.28B$89.01B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 77.5% of operating cash flow. Dividends came to 107.7% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$11.70B$12.74B$8.70B$29.27B$32.58B$14.40B$12.59B$15.83B$16.80B$16.19B
    Capital expenditures$2.63B$2.91B$3.91B$3.24B$2.71B$2.23B$2.05B$1.98B$1.96B$1.82B
    Free cash flow$9.07B$9.84B$4.79B$26.03B$29.87B$12.18B$10.54B$13.84B$14.85B$14.37B
    Dividends paid$9.77B$9.51B$9.25B$8.98B$8.73B$8.44B$8.04B$7.98B$7.66B$7.32B
    Share repurchasesN/AN/AN/A$2.00B$0$0$8.87B$12.20B$5.00B$5.00B
    Investing cash flow-$1.35B$2.65B-$32.28B-$15.78B-$22.55B-$4.27B-$3.94B$4.53B-$4.74B-$7.79B
    Financing cash flow-$10.30B-$17.14B$26.07B-$14.83B-$9.82B-$9.65B-$8.48B-$20.44B-$13.35B-$9.23B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$5.38B$835.00M$2.62B$5.35B$4.60B-$582.00M$2.33B$6.72B$6.71B-$1.78B$1.09B$5.24B
    Capital expenditures$573.00M$533.00M$436.00M$845.00M$602.00M$618.00M$564.00M$917.00M$651.00M$637.00M$704.00M$1.04B
    Free cash flow$4.80B$302.00M$2.18B$4.50B$4.00B-$1.20B$1.77B$5.80B$6.06B-$2.42B$386.00M$4.20B
    Last 12 quarters

    Frequently Asked Questions About PFE

    What is Pfizer's annual revenue?

    Pfizer reported revenue of $62.58B for the fiscal year ended Dec 31, 2025.

    How fast is Pfizer's revenue growing?

    Revenue was down 1.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -14.8%.

    Is Pfizer profitable?

    Yes. Pfizer reported net income of $7.81B for the fiscal year ended Dec 31, 2025, with a net margin of 12.5%.

    How much free cash flow does PFE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $11.70B minus capital expenditures of $2.63B produced free cash flow of $9.07B.

    How much debt does Pfizer have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $61.64B, short-term debt of $3.15B and cash and equivalents of $1.14B.